Form 8-K - Current report:
SEC Accession No. 0001839882-24-046555
Filing Date
2024-12-20
Accepted
2024-12-20 16:17:53
Documents
15
Period of Report
2024-12-20
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT tnxp-8k_122024.htm   iXBRL 8-K 25496
2 OPINION OF BROWNSTEIN HYATT FARBER SCHRECK, LLP ex5-01.htm EX-5.01 15189
6 GRAPHIC brownstein.jpg GRAPHIC 6158
  Complete submission text file 0001839882-24-046555.txt   225849

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tnxp-20241220.xsd EX-101.SCH 3024
4 XBRL LABEL FILE tnxp-20241220_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE tnxp-20241220_pre.xml EX-101.PRE 22365
17 EXTRACTED XBRL INSTANCE DOCUMENT tnxp-8k_122024_htm.xml XML 3541
Mailing Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928
Business Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36019 | Film No.: 241568195
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)